Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter R

Generic Name	Trade Name	Condition	Study Code	Study Name	Access to study	Access to results
RABBIT ANTI-THYMOCYTE GLOBULIN	Thymoglobulin	Myelodysplastic Syndrome	ThymoHEM01206	RISE	NCT00542828	Tabulated Results
RAMIPRIL	Triatec	Heart diseases	HOE498_3501	FOCUS	NCT00268619	Summary
RAMIPRIL	Triatec	Atherosclerosis	HOE498_4099	HOPE	NCT01053910	Summary
RAMIPRIL	Triatec	Glomerulonephritis	HOE498_6015	NA	NCT00437463	Summary
RAMIPRIL	Triatec	Hypertension	HOE498_3E03	PHARAO	NCT00325806	Publication's reference
RAMIPRIL	Triatec	Coronary Artery Disease	RAMIP_L_03123	HOPETips	NCT03099213	Summary
RAMPIRIL + FELODIPINE	Triapin	Hypertension	RAMFE_L_03420	NA	NCT00841880	Summary
RAMPIRIL + FELODIPINE	Triapin	Hypertension	RAMIP_L_01961	RAFE HELP	NCT00507845	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	ACT5080	NA	NCT00290992	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	ARD5290	NA	NCT00631579	Summary
RASBURICASE	Elitek, Fasturtec	Tumor lysis syndrome	EFC4978	NA	NCT00230178	Tabulated Results
RASBURICASE	Elitek, Fasturtec	Cancer, Hyperuricemia	EFC4978	NA	NCT00230178	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	EFC4983	GRAAL2	NCT00664144	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	EFC5339	NA	NCT00230217	Summary
RASBURICASE	Elitek, Fasturtec	Tumor lysis syndrome	L_8637	NA	NCT00651911	Summary
RASBURICASE	Elitek, Fasturtec	Hematologic neoplasms	L_8720	NA	NCT00563771	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	L_9436	NA	NCT00302653	Summary
RASBURICASE	Elitek, Fasturtec	Hyperuricemia	RASBU_L_00351	NA	NCT00607152	Summary
RHO-KINASE INHIBITOR	Not marketed	Erectile Dysfunction	ACT10775	RHOKET	EudraCT: 2009-009936-56	Summary Results
RIFAPENTINE	Priftin	Tuberculosis	INT12291	NA	NCT01690403	Summary
RILUZOLE	Rilutek	Amyotrophic Lateral Sclerosis	RIL_CA1_401	CARE	NCT00542412	Summary
RILUZOLE	Rilutek	Amyotrophic Lateral Sclerosis	RIL_DE1_201	NA	NCT00277602	Summary 1 Summary 2
RIFERMINOGENE PECAPLASMID	Not marketed	Critical limb ischemia	EFC6145	TAMARIS	NCT00566657	Publication's reference
RIMONABANT	Acomplia	Obesity	ACT3801	NA	NCT00481975	Summary
RIMONABANT	Acomplia	Obesity	DRI5747	NA	NCT00459004	Summary
RIMONABANT	Acomplia	Obesity	EFC4733	RIO-EUROPE	NCT00386061	Publication's reference
RIMONABANT	Acomplia	Obesity	EFC4735	RIO-LIPIDS	NCT00029835	Publication's reference
RIMONABANT	Acomplia	Obesity	EFC4736	RIO-DIABETES	NCT00029848	Publication's reference
RIMONABANT	Acomplia	Obesity	EFC4743	RIO-NORTH AMERICA	NCT00029861	Publication's reference
RIMONABANT	Acomplia	Smoking Cessation	EFC4796	STRATUS-WW	NCT00459173	Summary
RIMONABANT	Acomplia	Obesity	EFC4798	CIRRUS	NCT00458718	Abstract
RIMONABANT	Acomplia	Diabetes, Type 2	EFC5593	ARPEGGIO	EudraCT: 2005-001613-17	Summary Results
RIMONABANT	Acomplia	Obesity Dyslipidemia	EFC5823	ADAGIO	EudraCT: 2005-000807-33	Summary Results
RIMONABANT	Acomplia	Obesity	EFC5827	STRADIVARIUS	NCT00124332	Publication's reference
RIMONABANT	Acomplia	Obesity	EFC6001	RIO-ASIA	NCT00325546	Summary
RIMONABANT	Acomplia	Obesity	RIMON_R_00961	PRADO	NCT00405808	Summary
RISEDRONATE SODIUM	Actonel	Osteoporosis, Postmenopausal	EFC6063 (HMR4003B/4003)	NA	NCT00358176	Summary
RISEDRONATE SODIUM	Actonel	Osteoporosis, Postmenopausal	EFC6064	NA	NCT00353080	Summary
RISEDRONATE SODIUM	Actonel	Osteoporosis	HMR4003B_3507	OSMAUSE	EudraCT: 2005-005598-30	Summary Results
RISEDRONATE SODIUM	Actonel	Osteoporosis	HMR4003B_4001	IMPACT	NCT00268632	Summary
RISEDRONATE SODIUM	Actonel	Osteoporosis, Postmenopausal	HMR4003F/4001	NA	NCT00402441	Summary
RISEDRONATE SODIUM	Actonel	Osteoporosis, Postmenopausal	RISED_L_01930	SOLID	NCT00460733	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_2501	NA	NCT00351091	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4027	ACTIVATE	NCT00616694	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4031	POWER	NCT00549068	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4033	NA	NCT00790101	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4034	OPTAMISE	EudraCT: 2004-002317-37	Summary Results
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4035	NA	NCT00549965	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	HMR4003B_4036	NA	NCT00453492	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	RISED_L_01054	NA	NCT00632216	Summary
RISEDRONATE SODIUM	Actonel	Bone Diseases	RISED_L_01686	ROSPA	NCT00544180	Summary

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted

Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Follow us